[
Abstract]
[
Full Text PDF] （in Japanese / 675KB）
[Members Only And Two Factor Auth.] J.Jpn. Surg. Soc.. 88(11): 1624-1631, 1987
Original article
BREAST CANCER-SPECIFIC IMMUNITY EVALUATED BY A NEW IN VITRO METHOD―IL-2 ENHANCED MLTR
Peripheral blood lymphocytes from 81 patients with breast cancer were stimulated in vitro with solubilized sonicated autologous tumor extract as an antigen sosurse. The significance of tumor. stimulation (mixed lymphocyte tumor reaction ; MLTR) was evaluated with or without the addition of interleukin-2 (IL-2, 90 U/ml). As a result, MLTR with the addition of IL-2 (IL-2 enhanced MLTR) showed a higher significance even at a stimulation index (S.I.) of 1.5 than MLTR without IL-2. The values of S.I. in IL-2 enhanced MLTR in preoperative cancer patients were the highest in the patients without lymph node metastasis (n
0). The patients with advanced lymph node metastasis (n
2) showed a lower response preoperatively but their response was similar to that of the no-patients l to 2 was after operation. These difference were not observed in the blastogenic response to IL-2. These results suggest that IL-2 enhanced MLTR is a useful method to assess the tumor-specific immunological status of the cancer patients.
To read the PDF file you will need Adobe Reader installed on your computer.